ASX Release

Annual General Meeting – Chairman Address

Melbourne, Australia (20 November 2017)

Good morning Ladies and Gentlemen,

My name is Steve Engle, and I have the pleasure of serving as Chairman of Prescient Therapeutics.

Prescient Therapeutics is a company dedicated to developing and delivering drug therapies that treat multiple types of cancer, with the ability to provide solutions to drug resistant problems that are experienced with current front line chemotherapies. During the 2016-2017 financial year, our novel compounds, PTX-200 and PTX-100, showed significant potential in achieving this and I am pleased to share this progress with you today.

As many of you know, our lead candidate, PTX-200, has been in clinical trials testing its efficacy in ovarian and breast cancer as well as Acute Myeloid Leukaemia (or AML). At the end of 2016, the Company announced progress across these pipelines; following positive Phase 1 results, the Company initiated of a Phase 1b/2 for AML at the world-class Moffitt Cancer, Yale Cancer and Kansas University Medical centres under the leadership of Principal Investigator, Professor Jeffrey Lancet. We feel very fortunate to work so closely with Professor Lancet, an internationally recognized haematologist with deep clinical experience.

In the new year, bolstering our intellectual property portfolio was a key accomplishment. In March, we were pleased to receive three additional US patents protecting our platform's method of treatments as well as, in May, another key patent in Europe that provides broad platform technology protection for PTX-200 and strengthened of our proprietary position.

Also in May, the Company secured Orphan Drug Designation for PTX-200's treatment of AML from the Office of Orphan Products Development at the U.S. Food and Drug Administration (or FDA). The Orphan Drug Designation program recognises drugs that are defined as safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the US – as is the case with AML. Securing this designation is a significant milestone for Prescient, and the benefits of the designation include market exclusivity rights, a 50% tax credit on U.S. clinical trial expenses, and the potential for accelerated review in the future.

While solid progress was made across our three PTX-200 studies, unfortunately, in May, the Company experienced a setback that resulted in a clinical hold across all studies, putting a delay on the programs. Events of this nature are not unusual in oncology clinical studies where patients are very ill, however, the Company was extremely prudent in its response and paused the trials to review the clinical protocols and risk mitigation plans both internally and with the regulatory authorities. Our management team, have been in close contact with the FDA for this process and, subsequent to year end, we announced the lift of clinical holds for both the AML and ovarian cancer trials.

Further, our second drug candidate, PTX-100, was also highlighted during the year, with a pre-clinical study being published in the prestigious scientific journal, *Nature*, in June. The study published indicates that PTX-100 plays a key role in mitigating a recently discovered cancer pathway. This implication opens up a breadth of clinical possibilities for PTX-100.

Management was active sharing these advancements both in Australia and the US, as well as spreading brand awareness across various investor markets, attending the Biotech Showcase 2017, the ROTH conference, and the Rodman & Renshaw Global Investment Conference during the year. We will continue to grow the relationships with these audiences in the coming year.

On behalf of the Board, I want to thank the dedicated physicians and many patients involved in our studies around the world. In addition, thank you to our investors, who support Prescient's vision with continued confidence in our Company.

Lastly, thank you to my fellow board members, our CEO Steven Yatomi-Clarke, and the entire Management team for your tireless dedication and hard work.

We are anticipating an exciting year, and I look forward to sharing our progress with you.

Thank you.

About Prescient Therapeutics Limited (Prescient)

Prescient is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Prescient's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapsed and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt); Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD.

Prescient is also conducting a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt, currently on clinical hold. The third trial is a Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It inhibits the activation of Rho, Rac and Rho circuits in cancer cells, which act as key oncogenic pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors and will be the focus of studies in rare hematological malignancies, namely RhoA mutant lymphomas.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
+61 401 018 828

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.